341 related articles for article (PubMed ID: 36101415)
1. B-Type Natriuretic Peptide (BNP) Revisited-Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?
Nishikimi T; Nakagawa Y
Biology (Basel); 2022 Jul; 11(7):. PubMed ID: 36101415
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
Vasquez N; Carter S; Grodin JL
Curr Heart Fail Rep; 2020 Jun; 17(3):67-76. PubMed ID: 32394149
[TBL] [Abstract][Full Text] [Related]
3. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
[TBL] [Abstract][Full Text] [Related]
4. Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter.
Semenov AG; Katrukha AG
Clin Chem; 2016 Apr; 62(4):617-22. PubMed ID: 26864319
[TBL] [Abstract][Full Text] [Related]
5. Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.
Arfsten H; Goliasch G; Bartko PE; Prausmüller S; Spinka G; Cho A; Novak J; Haslacher H; Strunk G; Struck J; Hülsmann M; Pavo N
Br J Clin Pharmacol; 2021 Mar; 87(3):916-924. PubMed ID: 32598074
[TBL] [Abstract][Full Text] [Related]
6. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
[TBL] [Abstract][Full Text] [Related]
7. Atrial and brain natriuretic peptides: Hormones secreted from the heart.
Nakagawa Y; Nishikimi T; Kuwahara K
Peptides; 2019 Jan; 111():18-25. PubMed ID: 29859763
[TBL] [Abstract][Full Text] [Related]
8. New issues on measurement of B-type natriuretic peptides.
Clerico A; Zaninotto M; Passino C; Plebani M
Clin Chem Lab Med; 2017 Nov; 56(1):32-39. PubMed ID: 28809748
[TBL] [Abstract][Full Text] [Related]
9. BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era.
Sbolli M; deFilippi C
Curr Cardiol Rep; 2020 Sep; 22(11):150. PubMed ID: 32951154
[TBL] [Abstract][Full Text] [Related]
10. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
11. Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?
Lippi G; Sanchis-Gomar F
Int J Cardiol; 2016 Sep; 219():111-4. PubMed ID: 27317994
[TBL] [Abstract][Full Text] [Related]
12. B-type Natriuretic Peptide circulating forms: Analytical and bioactivity issues.
Yandle TG; Richards AM
Clin Chim Acta; 2015 Aug; 448():195-205. PubMed ID: 26160054
[TBL] [Abstract][Full Text] [Related]
13. Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy.
Maisel AS; Daniels LB; Anand IS; McCullough PA; Chow SL
Postgrad Med; 2018 Apr; 130(3):299-307. PubMed ID: 29596012
[TBL] [Abstract][Full Text] [Related]
14. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.
Ibrahim NE; McCarthy CP; Shrestha S; Gaggin HK; Mukai R; Szymonifka J; Apple FS; Burnett JC; Iyer S; Januzzi JL
J Am Coll Cardiol; 2019 Mar; 73(11):1273-1284. PubMed ID: 30898202
[TBL] [Abstract][Full Text] [Related]
15. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau J; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2013 Sep; 15(9):1062-73. PubMed ID: 23563576
[TBL] [Abstract][Full Text] [Related]
16. Potential pitfalls when interpreting plasma BNP levels in heart failure practice.
Nishikimi T; Nakagawa Y
J Cardiol; 2021 Oct; 78(4):269-274. PubMed ID: 34088563
[TBL] [Abstract][Full Text] [Related]
17. Brain Natriuretic Peptide and Its Biochemical, Analytical, and Clinical Issues in Heart Failure: A Narrative Review.
Fu S; Ping P; Zhu Q; Ye P; Luo L
Front Physiol; 2018; 9():692. PubMed ID: 29922182
[TBL] [Abstract][Full Text] [Related]
18. Interpretation of B-type natriuretic peptides in the era of angiotensin receptor-neprilysin inhibitors.
Bettencourt P; Fonseca C; Franco F; Andrade A; Brito D
Rev Port Cardiol; 2017 Dec; 36(12):881-884. PubMed ID: 29225105
[TBL] [Abstract][Full Text] [Related]
19. Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction.
Okutucu S; Fatihoglu SG; Sabanoglu C; Bursa N; Sayin BY; Aksoy H; Oto A
Herz; 2021 Apr; 46(Suppl 1):69-74. PubMed ID: 31796977
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]